Lineage Therapeutics Report issue

For profit Phase 2
Founded: Jerusalem Israel (2005)
Status: Acquired by Impax Laboratories (2012) → now Amneal Pharmaceuticals (2017)

Organization Overview

First Clinical Trial
2015
NCT02286089
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Cell Cure Neurosciences Ltd.

Active Ingredients

Drugs in Phase 2 Trials (1)

opregen (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Geographic Atrophy (Phase 2)

Macular Degeneration (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1